CABA · Cabaletta Bio, Inc. · Financials
$2.97
-0.30 (-9.30%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we have concluded that substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$565.43M
Shares
169.55M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$167.86M
-44.9%
FY2025
Diluted EPS
-$2.10
+10.3%
FY2025
Operating Cash Flow
-$131.08M
-48.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $157.8M | $142.67M | $97.2M | $55.42M | $39.3M | $32.49M | $21.38M | $11.67M | $4.47M | |
| $27.72M | $29.57M | $27.94M | $19.24M | $14.84M | $13.82M | $12.46M | $7.01M | $1.73M | |
| $185.52M | $172.24M | $125.14M | $74.66M | $54.14M | $46.31M | $33.83M | $18.68M | $6.19M | |
| -$185.52M | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M | -$33.83M | -$18.68M | -$6.19M | |
| $2.29M | $2M | $748K | $0 | — | — | — | — | — | |
| $5.81M | $6.03M | $10.03M | $6.99M | $1.16M | $24K | $494K | $1.74M | $235K | |
| $0 | $0 | $0 | — | — | — | — | — | — | |
| -$181.32M | -$167.86M | -$115.86M | -$67.68M | -$52.98M | -$46.29M | -$33.34M | -$16.94M | -$12.2M | |
| — | — | — | — | — | — | -$33.34M | -$22.27M | -$12.2M | |
| -$181.32M | -$167.83M | -$115.9M | -$67.59M | -$53.02M | -$46.29M | -$33.33M | -$22.27M | — | |
| USD/shares | -$1.39 | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | — | — | — |
| USD/shares | -$1.39 | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | — | — | — |
| shares | — | — | — | 1.17M | 5.94M | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.04×
EV/EBIT
—
Peer median 10.56×
P/E (TTM)
—
Peer median 12.88×
Peer medians compare against the 313 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1759138
CUSIP
12674W109
13F (30d)
104 filings
104 filers
Visit website
Investor relations